Oral Answers to Questions

Bill Grant Excerpts

Tuesday 29th October 2019 Commons Chamber

[Matt Hancock]

The NHS is off the table in trade talks and pharmaceutical pricing is off the table. Transparency over pharmaceutical pricing would not benefit this country at all because we get the best deals in the world because we can keep them confidential, so it is a slight surprise to hear a Labour Member argue for what would effectively lead to higher prices for drugs in the NHS. Instead, we will protect the NHS.

[Bill Grant (Ayr, Carrick and Cumnock) (Con)]

5. What recent assessment he has made of the merits of using genomics in healthcare.

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

We are world leading in genomics and should celebrate that. A recent trial at Addenbrooke’s Hospital in Cambridge provided whole genome sequencing, identifying underlying genetic conditions for babies and children in intensive care. As a result, three quarters of those young patients received changes to their care. The NHS genomic service is working to embed genomics in routine healthcare. Later this year, the national genomic healthcare strategy will set out the ambitious programme for the next 10 years.

[Bill Grant]

With increasing direct-to-consumer genomic testing by private companies, can my hon. Friend advise what assessment has been made of the potential impact of self-referrals on NHS services?

[Jo Churchill]

Patients who need a genomic test from the national genomic test directory will be referred to the NHS genomic medicine service. However, I recognise that some patients may contact their GP for advice after taking a commercial test. NHS England is working with partners to ensure that GPs receive training to help them respond correctly. Public Health England and the National Screening Committee have also published guidance on private screening.